Persistent renal dysfunction (PRD) has been reported in up to 22% of perinatally HIV-infected adolescents (PHAs) in the United States and Europe. There are limited data available on PRD among PHAs in resource-limited settings regarding access to antiretroviral therapy (ART) at more advanced HIV stages.Methods:
We retrospectively described the prevalence of PRD and associated factors in a Thai PHA cohort. Inclusion criteria were current age ≥10 years old and at least 2 serum creatinine (Cr) measurements after ART initiation. Cr and urine examination were performed every 6–12 months. PRD was defined as having ≥2 measurements of low estimated glomerular filtration rate (eGFR); either <60 mL/min/1.73 m2 or elevated Cr for age and eGFR 60–89 mL/min/1.73 m2, or proteinuria (dipstick proteinuria ≥1+). Factors associated with PRD were analyzed using a multivariate logistic regression analysis.Results:
This study included 255 PHAs with median (interquartile range) age of 16.7 (14.5–18.8) and ART duration of 10.3 (7.1–12.4) years. Fifty-six percentage used boosted protease inhibitor (bPI)–based regimens, and 63% used tenofovir disoproxil fumarate (TDF). The overall PRD prevalence was 14.1% [95% confidence interval (CI): 10.1–19.0]; low eGFR 6.7%, proteinuria 3.5% and both 3.9%. Among 109 users of TDF with bPI, 22.9% had PRD and 2.8% discontinued/adjusted dosing of TDF because of nephrotoxicity. Factors associated with PRD were age 10–15 years old (adjusted odd ratio (aOR): 10.1, 95% CI: 4.1–25.2), male (aOR: 3.2, 95% CI: 1.4–7.7), CD4 nadir <150 cells/mm3 (aOR: 2.6, 95% CI: 1.1–6.1) and use of TDF with bPI (aOR: 9.6, 95% CI: 3.2–28.9).Conclusions:
PRD is common among PHAs. Almost one-fifth of adolescents using TDF with bPI had PRD. These adolescents should be a priority group for renal monitoring.